Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE: Multidrug efflux pumps such as ABCG2 confer drug resistance to a number of cancer types, leading to poor prognosis and outcome. To date, the strategy of directly inhibiting multidrug efflux pumps in order to overcome drug resistance in cancer has been unsuccessful. An alternative strategy is to target proteins involved in the regulation of multidrug efflux pump activity or expression. Pim1 kinase has been demonstrated to phosphorylate ABCG2, promote its oligomerisation and contribute to its ability to confer drug resistance. METHODS: In the present manuscript, imidazo-pyridazine-based inhibitors of Pim1 were examined for their ability to overcome ABCG2-mediated drug resistance. Drug efficacy was measured as a cytotoxic response or an effect on transport by ABCG2. Protein expression patterns were assessed using western immuno-blotting. RESULTS: The two Pim1 inhibitors increased the potency of flavopiridol, mitoxantrone, topotecan and doxorubicin, specifically in ABCG2-expressing cells. This effect was associated with an increase in the cellular accumulation of [(3)H]-mitoxantrone, suggesting direct impairment of the transporter. However, prolonged pre-incubation with the studied inhibitors greatly enhanced the effect on mitoxantrone accumulation. The inhibitors caused a significant time-dependent reduction in the expression of ABCG2 in the resistant cells, an effect that would improve drug efficacy. CONCLUSION: Consequently, it appears that the Pim1 inhibitors display a dual-mode effect on ABCG2-expressing cancer cells. This may provide a powerful new strategy in overcoming drug resistance by targeting proteins that regulate expression of efflux pumps.

Original publication

DOI

10.1007/s00280-015-2858-9

Type

Journal article

Journal

Cancer Chemother Pharmacol

Publication Date

10/2015

Volume

76

Pages

853 - 864

Keywords

ABCG2, BCRP, Cancer chemotherapy, Multidrug resistance, Pim1 kinase, ATP Binding Cassette Transporter, Sub-Family G, Member 2, ATP-Binding Cassette Transporters, Antineoplastic Agents, Biological Transport, Cell Line, Tumor, Cell Proliferation, Cell Survival, Down-Regulation, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Drug Synergism, Drugs, Investigational, Humans, Imidazoles, Inhibitory Concentration 50, Kinetics, Neoplasm Proteins, Protein Kinase Inhibitors, Protein Transport, Proto-Oncogene Proteins c-pim-1, Pyridazines, Recombinant Proteins